Stocks · News reference
Truist Adjusts Price Target on Pediatrix Medical to $31 From $28
Truist has raised its price target for Pediatrix Medical Group, Inc. while maintaining a 'Hold' rating on the stock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pediatrix Medical Group (MD) Beats Q3 Earnings and Revenue Estimates
Pediatrix Medical Group reported Q3 2026 earnings of $0.72 per share, beating consensus estimates of $0.63 and surpassing revenue expectations. The company has outperformed the S&P 500 by 35.2% year-to-date. However, it received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, with the Medical Services industry ranking in the bottom 40% of sectors.
Midland Exploration Inc. Announces Results from Summer 2026 Diamond Drilling Campaign at Willbob Gold Project
Midland Exploration Inc. reported positive diamond drilling results from its 100%-owned Willbob gold project in the Labrador Trough, including multiple gold-bearing intervals.
Pediatrix Medical Group, Inc. Reports Q3 2026 Financial Results
Pediatrix Medical Group, Inc. reported third-quarter 2026 revenue of $501.4 million, exceeding the FactSet consensus estimate of $498.2 million.
8-K filing — Pediatrix Medical Group, Inc. (MD)
Filed: 2026-10-29 AccNo: 0001193125-26-436932 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Can Pediatrix Sustain Growth Despite Lower Patient Volumes?
Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.